In Vivo Estimation of Bioartificial Liver with Recombinant HepG2 Cells Using Pigs with Ischemic Liver Failure
Biological efficacy of a recombinant human hepatic cell line, glutamine synthetase transfected HepG2 (GS-HepG2), was examined with large-scale culture in a circulatory flow bioreactor and in pigs with ischemic liver failure. GS-HepG2 cells were cultured in a circulatory flow bioreactor from 5 × 107...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2001-05-01
|
| Series: | Cell Transplantation |
| Online Access: | https://doi.org/10.3727/000000001783986459 |
| _version_ | 1828880649005563904 |
|---|---|
| author | Shin Enosawa Tomoyuki Miyashita Yuji Fujita Seiichi Suzuki Hiroshi Amemiya Takeshi Omasa Shinya Hiramatsu Kenichi Suga Toshiharu Matsumura |
| author_facet | Shin Enosawa Tomoyuki Miyashita Yuji Fujita Seiichi Suzuki Hiroshi Amemiya Takeshi Omasa Shinya Hiramatsu Kenichi Suga Toshiharu Matsumura |
| author_sort | Shin Enosawa |
| collection | DOAJ |
| description | Biological efficacy of a recombinant human hepatic cell line, glutamine synthetase transfected HepG2 (GS-HepG2), was examined with large-scale culture in a circulatory flow bioreactor and in pigs with ischemic liver failure. GS-HepG2 cells were cultured in a circulatory flow bioreactor from 5 × 107 to 4 × 109 cells for 109 days. The cells showed ammonia removal activity even under substrate (glutamic acid)-free medium, suggesting that the GS catalyzed the activity using intracellular glutamic acid that had been pooled during conventional culture. When GS-HepG2 bioartificial liver (BAL) was applied to pigs with ischemic liver failure, survival time was prolonged to 18.8 ± 6.1 h (mean ± SD, n = 4) from 13.8 ± 5.4 h (n = 6) and 10.7 ± 4.1 h (n = 6) (groups treated with cell-free BAL and treated with plasma exchange and continuous hemodia-filtration, respectively). Laboratory data indicated the tendency for improvement in increase of blood ammonia level and decline of blood coagulation indices in the GS-HepG2 BAL-treated group. The advantages and potential for the cell line as a bioreactor in BAL is also discussed, comparing to those of isolated porcine hepatocytes. |
| first_indexed | 2024-12-13T09:51:51Z |
| format | Article |
| id | doaj.art-7a3645f0b5314feca868fedbdfc24c58 |
| institution | Directory Open Access Journal |
| issn | 0963-6897 1555-3892 |
| language | English |
| last_indexed | 2024-12-13T09:51:51Z |
| publishDate | 2001-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cell Transplantation |
| spelling | doaj.art-7a3645f0b5314feca868fedbdfc24c582022-12-21T23:51:54ZengSAGE PublishingCell Transplantation0963-68971555-38922001-05-011010.3727/000000001783986459In Vivo Estimation of Bioartificial Liver with Recombinant HepG2 Cells Using Pigs with Ischemic Liver FailureShin Enosawa0Tomoyuki Miyashita1Yuji Fujita2Seiichi Suzuki3Hiroshi Amemiya4Takeshi Omasa5Shinya Hiramatsu6Kenichi Suga7Toshiharu Matsumura8National Children's Medical Research CenterNational Children's Medical Research CenterNational Children's Medical Research CenterNational Children's Medical Research CenterNational Children's Medical Research CenterUniversity of Osaka, Graduate School of TechnologyUniversity of Osaka, Graduate School of TechnologyUniversity of Osaka, Graduate School of TechnologyMeiji Institute of Health ScienceBiological efficacy of a recombinant human hepatic cell line, glutamine synthetase transfected HepG2 (GS-HepG2), was examined with large-scale culture in a circulatory flow bioreactor and in pigs with ischemic liver failure. GS-HepG2 cells were cultured in a circulatory flow bioreactor from 5 × 107 to 4 × 109 cells for 109 days. The cells showed ammonia removal activity even under substrate (glutamic acid)-free medium, suggesting that the GS catalyzed the activity using intracellular glutamic acid that had been pooled during conventional culture. When GS-HepG2 bioartificial liver (BAL) was applied to pigs with ischemic liver failure, survival time was prolonged to 18.8 ± 6.1 h (mean ± SD, n = 4) from 13.8 ± 5.4 h (n = 6) and 10.7 ± 4.1 h (n = 6) (groups treated with cell-free BAL and treated with plasma exchange and continuous hemodia-filtration, respectively). Laboratory data indicated the tendency for improvement in increase of blood ammonia level and decline of blood coagulation indices in the GS-HepG2 BAL-treated group. The advantages and potential for the cell line as a bioreactor in BAL is also discussed, comparing to those of isolated porcine hepatocytes.https://doi.org/10.3727/000000001783986459 |
| spellingShingle | Shin Enosawa Tomoyuki Miyashita Yuji Fujita Seiichi Suzuki Hiroshi Amemiya Takeshi Omasa Shinya Hiramatsu Kenichi Suga Toshiharu Matsumura In Vivo Estimation of Bioartificial Liver with Recombinant HepG2 Cells Using Pigs with Ischemic Liver Failure Cell Transplantation |
| title | In Vivo Estimation of Bioartificial Liver with Recombinant HepG2 Cells Using Pigs with Ischemic Liver Failure |
| title_full | In Vivo Estimation of Bioartificial Liver with Recombinant HepG2 Cells Using Pigs with Ischemic Liver Failure |
| title_fullStr | In Vivo Estimation of Bioartificial Liver with Recombinant HepG2 Cells Using Pigs with Ischemic Liver Failure |
| title_full_unstemmed | In Vivo Estimation of Bioartificial Liver with Recombinant HepG2 Cells Using Pigs with Ischemic Liver Failure |
| title_short | In Vivo Estimation of Bioartificial Liver with Recombinant HepG2 Cells Using Pigs with Ischemic Liver Failure |
| title_sort | in vivo estimation of bioartificial liver with recombinant hepg2 cells using pigs with ischemic liver failure |
| url | https://doi.org/10.3727/000000001783986459 |
| work_keys_str_mv | AT shinenosawa invivoestimationofbioartificialliverwithrecombinanthepg2cellsusingpigswithischemicliverfailure AT tomoyukimiyashita invivoestimationofbioartificialliverwithrecombinanthepg2cellsusingpigswithischemicliverfailure AT yujifujita invivoestimationofbioartificialliverwithrecombinanthepg2cellsusingpigswithischemicliverfailure AT seiichisuzuki invivoestimationofbioartificialliverwithrecombinanthepg2cellsusingpigswithischemicliverfailure AT hiroshiamemiya invivoestimationofbioartificialliverwithrecombinanthepg2cellsusingpigswithischemicliverfailure AT takeshiomasa invivoestimationofbioartificialliverwithrecombinanthepg2cellsusingpigswithischemicliverfailure AT shinyahiramatsu invivoestimationofbioartificialliverwithrecombinanthepg2cellsusingpigswithischemicliverfailure AT kenichisuga invivoestimationofbioartificialliverwithrecombinanthepg2cellsusingpigswithischemicliverfailure AT toshiharumatsumura invivoestimationofbioartificialliverwithrecombinanthepg2cellsusingpigswithischemicliverfailure |